Pomerantz Law Firm Files Class Action Against Aldeyra Therapeutics for Shareholder Protection

Pomerantz Law Firm Takes Action on Behalf of Aldeyra Investors

In a significant move aimed at protecting investors, Pomerantz LLP—a renowned firm specializing in securities class actions—has filed a class action lawsuit against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX). This legal action has emerged in response to allegations that Aldeyra and certain officers or directors may have engaged in securities fraud or other illicit business practices. Pomerantz is urging those who incurred losses as a result of their investment in Aldeyra to step forward before the approaching deadline of May 29, 2026.

Context Surrounding the Lawsuit

The root of the lawsuit rests on a troubling report released by Aldeyra on March 17, 2026, which revealed the receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA). This letter was concerning Aldeyra's New Drug Application (NDA) for reproxalap, a candidate drug aimed at treating dry eye disease. The FDA’s correspondence highlighted a lack of sufficient evidence supporting the drug’s claims of efficacy, raising significant doubts about its intended benefits and questioning the reliability of study results. Following this announcement, Aldeyra's stock plummeted by $2.99—or 70.69%—closing at just $1.24 per share.

Implications for Investors

Given the sharp decline in stock price and the adverse news regarding the drug's approval, investors who purchased Aldeyra securities during the designated Class Period may have a legal avenue to seek compensation. Pomerantz urges affected investors to express their interest in becoming Lead Plaintiffs for the class action, which represents a collective effort to hold the company accountable for its actions. Potential participants can request additional information by contacting Pomerantz directly.

Ongoing Commitment to Investor Rights

Pomerantz LLP, based in New York with extended offices in major cities globally, has built a reputation over its 85 years of existence as a leader in securities class litigation. The firm, founded by Abraham L. Pomerantz, has been at the forefront of fighting for the rights of investors, particularly in cases of securities fraud and corporate misconduct. It is dedicated to ensuring that justice is served for victims of breaches of fiduciary duty and illicit corporate actions.

“Protecting the rights of investors is at the heart of what we do,” said Danielle Peyton, an attorney at Pomerantz. “We encourage anyone impacted by the recent events surrounding Aldeyra to reach out and explore their options.”

Conclusion

As the deadline for potential plaintiffs approaches, those who invested in Aldeyra Therapeutics in a time of rising optimism now face challenges due to the recent ruling by the FDA. The upcoming class action represents a pivotal opportunity for investors seeking redress for their losses. Anyone interested in joining this collective legal action is encouraged to act swiftly, keeping in mind the deadline provided by Pomerantz LLP.

For further inquiries or to discuss your case, reach out to Pomerantz LLP at email or call their toll-free number, 888.4-POMLAW, Extension 7980.